Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Recursion's Fast-Track Road to Therapeutics Using AI-Based Maps of Biology
Recursion's AI platform developed REC-1245, a drug for solid tumors and lymphoma, progressing from target to preclinical candidate in under 18 months. The drug selectively degrades RBM39, offering a new therapeutic approach for resistant tumors. Industry experts note the potential of AI in speeding up drug discovery timelines, though the impact on phase transition likelihood remains uncertain.
Johnson & Johnson MedTech Launches VOLT™ Plating System
Johnson & Johnson MedTech launches VOLT™ Variable Angle Optimized Locking Technology Plating System, designed to improve stability and efficiency in fracture care. The system offers enhanced construct stability, a range of plate shapes, and color-coded instruments for improved surgical workflow. Available initially for mini and small fragment fractures, with additional anatomic solutions planned for 2025.
Other news to note for Oct. 10, 2024
Biopharma updates: deals, partnerships, grants, preclinical data, and other news involving Alkem, Astellas, Bio-Thera, Boehringer, Ciconia, Circle Pharma, Eli Lilly, Gedeon Richter, Gemma, Insitro, Johnson & Johnson, Nona, Overt Bio, Qinotto, Sonnet, Sumitomo, Takeda, Xortx.
Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?
FDA mandates breast density notification; CAR T-cell therapy linked to secondary cancers; breast cancer survivor creates documentary; piano lessons may alleviate chemotherapy brain fog; Johnson & Johnson halts bladder cancer trial; Merck's Keytruda improves head and neck cancer survival; Pfizer's Talzenna plus Xtandi extends prostate cancer survival; breast cancer treatments accelerate aging biomarkers; 3D-printed breast prosthesis detects tumor recurrence; industry funding for cancer trials raises concerns; Iranian cancer researchers under scrutiny; blood test predicts prostate cancer survival.
EU Approval Sought for D-VRd in Newly Diagnosed Myeloma
A Type II variation application for D-VRd (daratumumab, bortezomib, lenalidomide, dexamethasone) has been submitted to the EMA for newly diagnosed multiple myeloma patients. The submission is supported by the phase 3 CEPHEUS trial, which showed higher minimal residual disease negativity rates with D-VRd compared to VRd alone. The FDA has already approved D-VRd for induction and consolidation in ASCT candidates, based on the PERSEUS trial.
Related Clinical Trials:
Drug companies reluctantly accept state price negotiations
The Inflation Reduction Act (IRA) allows Medicare to negotiate drug prices with pharmaceutical firms, sparking industry lawsuits and warnings of stifling innovation. Negotiations on the first 10 drugs are complete, with government estimates of $6 billion savings in 2023. Legal challenges argue the IRA is unconstitutional, while some industry voices express reluctant acceptance. The law could alter R&D strategies and regulatory approaches, potentially skewing towards biological drugs. Critics argue the IRA could curb innovation, while others see it as a necessary shift towards valuing truly innovative medicines.
Biogen scores breakthrough status for anti-rejection transplant medication
FDA grants Biogen's monoclonal antibody felzartamab breakthrough therapy designation for treating late antibody-mediated rejection in kidney transplant patients, based on positive Phase II trial data. Biogen plans to initiate Phase III trials for felzartamab in multiple indications next year. The therapy, acquired through the $1.15bn HI-Bio acquisition, is expected to generate over $776m by 2032 if approved.
Related Clinical Trials:
Regeneron takes the long-haul approach to oncology, stumbles and all
Regeneron, despite being a latecomer in cancer therapies, aims to leverage its packed pipeline to become a leader in the next wave of oncology treatments. Dr. Israel Lowy, senior vice president of translational and clinical sciences in oncology, highlights the company's focus on combinations like Libtayo and fianlimab, which could rival existing treatments like Opdualag and Keytruda. Regeneron's journey includes pioneering bispecific antibodies and facing early challenges, but with ongoing clinical trials and collaborations, the company seeks to establish itself as a major player in cancer therapy.
J&J Says TREMFYA Showed Strong Results In Biologic-Naive & Refractory Patients With CD And UC
Johnson & Johnson's TREMFYA (guselkumab) shows high rates of endoscopic remission in Crohn's disease and ulcerative colitis, with 90% more biologic-naïve and three times more biologic-refractory UC patients achieving remission. TREMFYA is FDA-approved for UC and under review for CD, demonstrating superiority to ustekinumab in CD patients.
J&J Submits For EMA Approval For DARZALEX SC Quadruplet Regimen In Newly Diagnosed Multiple Myeloma
Janssen-Cilag International NV submits Type II variation application to EMA for DARZALEX SC formulation in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma, supported by Phase 3 CEPHEUS study data showing 60.9% MRD-negativity and 43% reduced risk of progression or death.
© Copyright 2025. All Rights Reserved by MedPath